- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03573271
Pivotal Study to Evaluate the Effectiveness of a Micro-coring Device Treating Moderate to Severe Facial Wrinkles
June 27, 2018 updated by: Cytrellis Biosystems, Inc.
A Prospective, Multi-center, Pivotal Study to Evaluate the Safety and Efficacy of a Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles
Study evaluating the effectiveness of a micro-coring device for the treatment of moderate to severe cheek wrinkles.
Study Overview
Detailed Description
Up to 60 subjects who meet the Inclusion/Exclusion criteria will be treated. All subjects will be monitored for a period of 90 days after treatments.
Evaluation results will be based in the following:
- Wrinkle severity score assessed using the Lemperle Wrinkle Scale
- Subject Satisfaction Scale
- PI Global Aesthetic Improvement Scale
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95816
- Active, not recruiting
- Laser and Skin Surgery Center of Northern California
-
-
Florida
-
Miami, Florida, United States, 33173
- Recruiting
- Miami Dermatology and Laser Institute
-
Contact:
- Nicole Rieth
- Phone Number: 305-279-6060
- Email: nicoler@miamidermlaser.com
-
-
New York
-
New York, New York, United States, 10016
- Not yet recruiting
- Laser and Skin Surgery Center of New York
-
Contact:
- Brittany Schmidt
- Phone Number: 212-686-7306
-
Principal Investigator:
- Roy Geroneumus, MD
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Active, not recruiting
- The Practice of Brian S. Biesman, M.D
-
-
Texas
-
Dallas, Texas, United States, 75231
- Not yet recruiting
- Dr A Jay Burns Cosmetic Surgery
-
Contact:
- Casey Martin
- Phone Number: 603-332-5211
-
Principal Investigator:
- A. Jay Burns, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females 40-70 years of age
- Fitzpatrick Skin Type I to IV as judged by the Investigator.
- Cheek areas are at least a score of 3 using the Lemperle Wrinkle Assessment Scale as judged by the Investigator
- Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits
Exclusion Criteria:
- Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma, vitiligo, cutaneous papules/nodules or active inflammatory lesions in the areas to be treated
- History of keloid formation or hypertrophic scarring
- History of trauma or surgery to the treatment areas in the past 6 months
- Scar present in the areas to be treated
- Silicone injections in the areas to be treated
- Injection of dermal fillers, fat or botulinum toxin, as well as any minimally invasive/invasive medical device for skin treatment, in the study treatment areas, within the past 6 months (i.e., dermabrasion, laser, RF devices)
- Active smokers (0.5 pack/day) or having quit within 3 months prior to treatment
- Active, chronic, or recurrent infection
- History of compromised immune system or currently being treated with immunosuppressive agents
- History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or epinephrine
- Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment
- Treatment with aspirin or other blood thinning agents within 14 days prior to treatment
- History or presence of any clinically significant bleeding disorder
- Any issue that, at the discretion of the Investigator, would interfere with assessment of safety or efficacy or compromise the subject's ability to participate in the study
- Treatment with an investigational device or agent within 30 days before treatment or during the study period
- Female and pregnant or plan on becoming pregnant during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Micro-coring of facial/neck skin with MCD
Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD
|
Micro-coring skin removal with automated coring device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess level of wrinkle improvement using the Lemperle Wrinkle Severity Scale at 90 days post treatment
Time Frame: 90 day post treatment
|
Assess level of wrinkle improvement from the baseline to 90 day post treatment an Independent Reviewer(s) using the Lemperle Wrinkle Severity Scale
|
90 day post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess safety profile by recording of adverse events
Time Frame: 90 days
|
Adverse events will be recorded throughout the study
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2018
Primary Completion (Anticipated)
January 15, 2019
Study Completion (Anticipated)
March 21, 2019
Study Registration Dates
First Submitted
June 14, 2018
First Submitted That Met QC Criteria
June 27, 2018
First Posted (Actual)
June 29, 2018
Study Record Updates
Last Update Posted (Actual)
June 29, 2018
Last Update Submitted That Met QC Criteria
June 27, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AIS 700-00041
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laxity; Skin
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Merz North America, Inc.Ulthera, IncCompletedMild to Moderate Skin Laxity Under the Chin | Mild to Moderate Skin Laxity on NeckUnited States
-
Apsara Medical CorporationCompleted
-
Ulthera, IncCompletedSkin Laxity of the décolletéUnited States
-
Ulthera, IncUniversity of Texas Southwestern Medical CenterCompletedMild to Moderate Skin Laxity on Cheek | Mild to Moderate Skin Laxity on Upper Neck | Mild to Moderate Subcutaneous Fat on Cheek | Mild to Moderate Subcutaneous Fat on Upper Neck
-
Derming SRLCompletedFace Skin LaxityItaly
-
Nashville Centre for Laser and Facial SurgeryBausch HealthUnknownFacial Skin Laxity
-
Ulthera, IncCompletedFacial Skin LaxityUnited States
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
Clinical Trials on MCD
-
Cytrellis Biosystems, Inc.Unknown
-
Cytrellis Biosystems, Inc.Unknown
-
Birmingham City UniversityCompleted
-
Goldfinch Bio, Inc.TerminatedDiabetic Nephropathies | Glomerulosclerosis, Focal Segmental | Minimal Change DiseaseUnited States
-
Cliniques universitaires Saint-Luc- Université...WithdrawnType 1 Diabetes MellitusBelgium
-
University Hospital, Basel, SwitzerlandCompleted
-
Washington University School of MedicineMedical Compression SystemsWithdrawnPE - Pulmonary Thromboembolism | DVT - Deep Vein Thrombosis